1988
DOI: 10.3109/10799898809048981
|View full text |Cite
|
Sign up to set email alerts
|

Interaction of the D1Receptor Antagonist Sch 23390 with the Central 5-HT System: Radioligang Binding Studies, Measurements of Biochemical Parameters and Effects on L-5-HTP Syndrome

Abstract: The interaction of SCH 23390 with dopamine (DA) and serotonin (5-HT) systems has been examined in vivo and in vitro. Like selective 5-HT2 blockers, SCH 23390 inhibited in vivo [3H]spiperone binding in the rat frontal cortex (ID50: 1.5 mg/kg) without interacting at D2 sites. SCH 23390 was equipotent to cinanserin and methysergide. In vitro, SCH 23390 inhibited [3H]ketanserin binding to 5-HT2 sites (IC50 = 30 nM). Biochemical parameters linked to DA and 5-HT were not changed excepted in striatum where SCH 23390 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
15
0

Year Published

1988
1988
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 40 publications
(15 citation statements)
references
References 14 publications
0
15
0
Order By: Relevance
“…In contrast, we observed that this dose of systemic D-amphetamine produced an inhibition of striatal ACh efflux when the D 1 receptor antagonist SCH 23390 concomitantly was applied in substantia nigra pars reticulata. Although it generally is accepted that SCH 23390 is a selective dopamine D 1 receptor antagonist in vivo, this drug does show significant affinity at 5-HT 2 receptors (Hyttel, 1984;Bischoff et al, 1988). Because D-amphetamine can act not only as a potent releaser of dopamine but also has weaker activity as a releaser of 5-HT (Raiteri et al, 1975;Kuczenski et al, 1995), there is the possibility that interactions of SCH 23390 and D-amphetamine with nigral 5-HT mechanisms could contribute to the present results.…”
Section: Discussionmentioning
confidence: 68%
“…In contrast, we observed that this dose of systemic D-amphetamine produced an inhibition of striatal ACh efflux when the D 1 receptor antagonist SCH 23390 concomitantly was applied in substantia nigra pars reticulata. Although it generally is accepted that SCH 23390 is a selective dopamine D 1 receptor antagonist in vivo, this drug does show significant affinity at 5-HT 2 receptors (Hyttel, 1984;Bischoff et al, 1988). Because D-amphetamine can act not only as a potent releaser of dopamine but also has weaker activity as a releaser of 5-HT (Raiteri et al, 1975;Kuczenski et al, 1995), there is the possibility that interactions of SCH 23390 and D-amphetamine with nigral 5-HT mechanisms could contribute to the present results.…”
Section: Discussionmentioning
confidence: 68%
“…tors (Bischoff et al 1986(Bischoff et al , 1988. Therefore, the impairments observed in the present study may be due to SCH23390 acting at 5-HT2 receptors.…”
Section: Prelimbic Cortex Learning and Dopaminementioning
confidence: 60%
“…Also, a spread of drug rostrally into the prelimbic-infralimbic cortex would not affect behavior, as these prefrontal subregions do not play a role in the form of decision making examined here: Walton et al (2003) demonstrated that excitotoxic lesions to the prelimbic-infralimbic cortex had no effect on rats' ability to make effort-based decisions. In addition, SCH23390 (Bischoff et al 1988) and eticlopride (Seeman and Ulpian 1988) are highly selective and potent antagonists at D1 or D2 receptors, respectively. Although SCH23390 displays affinity to 5-HT2 receptors as well (Bischoff et al 1988), actions on 5-HT2 receptors might not account for the SCH23390-induced behavioral effects.…”
Section: Discussionmentioning
confidence: 99%